Full text is available at the source.
Abstract
Psychedelic compounds like psilocybin, LSD, MDMA, and ketamine are increasingly recognized for their therapeutic potential in treating complex mental health conditions.
- Psychedelics may work by modulating serotonin receptors and altering brain connectivity.
- Each psychedelic has a unique pharmacological profile and specific clinical applications.
- Psilocybin and LSD engage similar serotonergic pathways but differ in how they affect receptors and subjective experiences.
- MDMA is associated with empathogenic properties, while ketamine may provide rapid antidepressant effects.
- Recent FDA designations for psilocybin and MDMA indicate a shift towards acceptance based on evidence.
- The field faces challenges including methodological limitations, regulatory hurdles, and ethical considerations.
Simplified